Navigation Links
Cytopia To Present Data on FMS Program With Anticancer Potential
Date:6/17/2008

MELBOURNE, Australia, June 18 /PRNewswire/ -- Cytopia Limited (ASX: CYT) will present details of its FMS drug discovery and development program at the Protein Kinase Targets conference, a leading conference for breakthrough scientific data on new kinase inhibitory drugs. This conference will be held from 23 to 25 June in Boston, USA.

This is the first scientific disclosure of data from the Cytopia FMS program and will be presented by Cytopia Senior Scientist Dr Michael Harte. Dr Harte's presentation is scheduled for 3:15 pm (US EDT) 25 June.

The presentation will describe the potent activity of a series of compounds discovered at Cytopia. These compounds inhibit the function of macrophages, key cells in the immune system and mediators of inflammatory reactions. As such these compounds have therapeutic potential in treating conditions such as rheumatoid arthritis. The inhibition of cells that are responsible for bone osteolysis in advanced cancer disease is also part of the physiological potential of FMS inhibitors.

Preliminary data on the potential of Cytopia's potent FMS inhibitors to treat advanced cancer in in vivo models will also be presented at this conference.

Cytopia CEO Mr Andrew Macdonald said, "We are very encouraged by the excellent preclinical profile of these compounds. This first public disclosure of our work raises the profile of this program to the broader scientific community and reflects the excellent science undertaken by the team."

This presentation is in the same month that Cytopia presented its CYT997 cancer findings to ASCO, the world's biggest oncology conference held in Chicago.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules with an improved therapeutic profile for the treatment of cancer. Cytopia's lead compound, CYT997, is currently in Phase II clinical trials.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cytopia Commences Phase II Cancer Drug Study
2. Gentiva(R) Health Services to Present June 24 at Jefferies 2nd Annual Healthcare Conference in New York
3. Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM)
4. Emageon to Present at the Jefferies 2nd Annual Healthcare Conference
5. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
6. VNUS Medical Technologies to Present at William Blair & Companys 28th Annual Growth Stock Conference
7. WebMD to Present at the William Blair 28th Annual Growth Stock Conference
8. Cardiva Medical, Inc. to Present at the Investment In Innovation (In3) Medical Device Summit on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
9. Digirad Corporation to Present at CapStone Small-Cap Investor Conference
10. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
11. EntreMed to Present at the BIO 2008 Annual International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
(Date:11/30/2016)... Wisconsin (PRWEB) , ... November 30, 2016 , ... ... in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of the ... year on the list, having ranked from 2008-2016. In addition, Standard Process was ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... and mental health treatment has announced the opening of a new residential mental ... for girls with mental health issues such as severe anxiety, depression, bi-polar disorder, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... stylish design wanted by today’s consumers at an affordable price, is now available ... the new watch is “a game changer” when it comes to the smartwatch. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2016  The Addiction Treatment Advisory Group (ATAG), ... Care Pharmacy (AMCP), has released detailed findings on ... opioid addiction crisis, including through improved access to ... ATAG,s newly released paper, "The Role of Managed ... many issues around gaps and barriers to addiction ...
(Date:12/2/2016)... 2, 2016 Boston Scientific Corporation (NYSE: ... acquire certain manufacturing assets and capabilities of the Neovasc, ... biological tissue business, as well as a 15% equity ... in cash. The Neovasc advanced biological tissue business makes ... Scientific Lotus™ Valve System. * Upon completion of ...
Breaking Medicine Technology: